Latest Articles
The Four Types of Therapy for Second-Line Endometrial Cancer - CancerNetwork
The Four Types of Therapy for Second-Line Endometrial Cancer CancerNetwork
Published: May 16, 2026, 2:04 p.m.
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor - Femtech Insider
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor Femtech Insider
Published: May 15, 2026, 11:33 a.m.
UM research team identifies novel targeted therapy for endometrial cancer - University of Macau
UM research team identifies novel targeted therapy for endometrial cancer University of Macau
Published: May 13, 2026, 3:13 a.m.
Managing Progression After Immunotherapy in Endometrial Cancer - OncLive
Managing Progression After Immunotherapy in Endometrial Cancer OncLive
Published: May 5, 2026, 12:07 p.m.
Foregoing SLN breast surgery does not lead to radiation therapy increase - AuntMinnie
Foregoing SLN breast surgery does not lead to radiation therapy increase AuntMinnie
Published: May 1, 2026, 4:19 p.m.
Metabolomic Markers of Neurotransmitter-Related Metabolism in Women with Ovarian Endometriomas: The Role of the Kynurenine Pathway and Changes During Progestin Therapy - EMJ
Metabolomic Markers of Neurotransmitter-Related Metabolism in Women with Ovarian Endometriomas: The Role of the Kynurenine Pathway and Changes During Progestin Therapy EMJ
Published: April 30, 2026, 6:19 a.m.
High response rates in platinum-resistant ovarian cancer with immunotherapy agents - MSN
High response rates in platinum-resistant ovarian cancer with immunotherapy agents MSN
Published: April 20, 2026, 8:14 a.m.
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer - Pharmacy Times
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer Pharmacy Times
Published: April 17, 2026, 12:30 p.m.
High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents - MedPage Today
High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents MedPage Today
Published: April 16, 2026, 7:11 p.m.
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy - TipRanks
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy TipRanks
Published: April 15, 2026, 1:38 p.m.
Link copied to clipboard!